China Pharma (NYSE:CPHI) Shares Gap Down – Here’s What Happened

China Pharma Holdings, Inc. (NYSE:CPHI) shares gapped down prior to trading on Tuesday . The stock had previously closed at $0.91, but opened at $0.86. China Pharma shares last traded at $13.3290, with a volume of 51,706,259 shares traded.

China Pharma Stock Performance

The company has a debt-to-equity ratio of 0.22, a current ratio of 0.79 and a quick ratio of 0.26. The business has a 50-day simple moving average of $0.78 and a 200-day simple moving average of $0.78. The firm has a market capitalization of $470.70 million, a PE ratio of -23.26 and a beta of 1.14.

Institutional Trading of China Pharma

A hedge fund recently raised its stake in China Pharma stock. Citadel Advisors LLC raised its position in shares of China Pharma Holdings, Inc. (NYSE:CPHI) by 31.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 30,426 shares of the company’s stock after acquiring an additional 7,356 shares during the period. Citadel Advisors LLC owned approximately 0.93% of China Pharma worth $59,000 as of its most recent filing with the Securities & Exchange Commission.

About China Pharma

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.